1197194-41-4 Usage
Description
Endoxifen (hydrochloride) is a potent and selective estrogen receptor modulator (SERM) that is a metabolite of tamoxifen, a widely used breast cancer treatment. It has demonstrated effectiveness in inhibiting the growth of estrogen receptor positive breast cancer cells and has shown promising results in preclinical studies. Endoxifen hydrochloride is being investigated for its potential as a targeted therapy for breast cancer and may offer fewer side effects compared to tamoxifen, making it a potential alternative for breast cancer treatment.
Uses
Used in Pharmaceutical Industry:
Endoxifen (hydrochloride) is used as a targeted therapy for breast cancer treatment due to its effectiveness in inhibiting the growth of estrogen receptor positive breast cancer cells. It is being investigated for its potential to offer fewer side effects compared to tamoxifen, making it a promising alternative for breast cancer treatment.
Used in Cancer Research:
Endoxifen (hydrochloride) is used as a subject of preclinical studies to explore its potential as a targeted therapy for breast cancer. Further research is ongoing to understand its mechanism of action and to determine its suitability for clinical use in breast cancer therapy.
Check Digit Verification of cas no
The CAS Registry Mumber 1197194-41-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,7,1,9 and 4 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1197194-41:
(9*1)+(8*1)+(7*9)+(6*7)+(5*1)+(4*9)+(3*4)+(2*4)+(1*1)=184
184 % 10 = 4
So 1197194-41-4 is a valid CAS Registry Number.
1197194-41-4Relevant articles and documents
Design of a platinum-acridine-endoxifen conjugate targeted at hormone-dependent breast cancer
Ding, Song,Qiao, Xin,Kucera, Gregory L.,Bierbach, Ulrich
supporting information, p. 2415 - 2417 (2013/04/23)
The synthesis of a novel pharmacophore comprising a DNA-targeted platinum-acridine hybrid agent and estrogen receptor-targeted 4-hydroxy-N-desmethyltamoxifen (endoxifen) using carbamate coupling chemistry and its evaluation in breast cancer cell lines are
